logo

DCAL vs INDOCO: Stock Comparison

DISHMAN CARBO AMCIS vs INDOCO REMEDIESUpdated 22 Oct 26, 4:08 PM ISTNSE & company filings

DISHMAN CARBO AMCIS is the larger company by market capitalisation. DISHMAN CARBO AMCIS shows a lower P/E, lower leverage and a higher net margin, while INDOCO REMEDIES shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

DCAL leads 5; INDOCO leads 6 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

DCALINDOCO

Valuation lens

What price are you paying?

Market CapContext only
₹2,195 Cr
₹2,077 Cr
P/E RatioDCAL has the lower reading
135.92x ✓
368.85x
P/B RatioDCAL has the lower reading
0.33x ✓
2.21x
EPSINDOCO has the higher reading
₹-3.69
₹7.04 ✓
Book ValueContext only
₹425.87
₹100.98
Dividend YieldINDOCO has the higher reading
0%
0.09% ✓

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
DCAL is the larger company
₹2,195 Cr vs ₹2,077 Cr
P/E Ratio
DCAL has a lower P/E
135.92x vs 368.85x
P/B Ratio
DCAL has a lower P/B
0.33x vs 2.21x
EPS
INDOCO has higher earnings per share
₹7.04 vs ₹-3.69
Dividend Yield
INDOCO has a higher dividend yield
0.09% vs 0%
Revenue Growth (TTM YoY)
INDOCO has faster revenue growth
21.9% vs 18.9%
EPS Growth (TTM YoY)
INDOCO has faster EPS growth
0% vs -49.5%
ROE
INDOCO has a higher ROE
-0.51% vs -0.99%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricDCALINDOCO
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricDCALINDOCO
Live Price₹140.02₹225.6
Day Change-1.46%-2.55%
Volume1.95 L1.07 L
52-Week High₹303₹291
52-Week Low₹128.5₹162.19
Distance from 52W High-53.79%-22.47%

Valuation

MetricDCALINDOCO
Market Cap₹2,195 Cr₹2,077 Cr
P/E Ratio135.92x368.85x
P/B Ratio0.33x2.21x
EPS₹-3.69₹7.04
Book Value₹425.87₹100.98
Dividend Yield0%0.09%

Growth

MetricDCALINDOCO
Revenue Growth (TTM YoY)18.9%21.9%
EPS Growth (TTM YoY)-49.5%0%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricDCALINDOCO
ROE-0.99%-0.51%
ROCE0.61%4.26%
Net Margin2.51%-5.31%
Operating Margin11.78%4.57%
Debt to Equity0.16x0.64x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricDCALINDOCO
Promoter Holding59.32%58.86%
FII Holding6.86%▼ 0.59 pp1.27%▲ 0.33 pp
DII Holding2.07%▲ 0.44 pp17.68%▼ 0.47 pp
Public Holding31.75%▲ 0.15 pp22.04%▲ 0.14 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: DISHMAN CARBO AMCIS and INDOCO REMEDIES.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.